Equelle for Hot Flashes: What the Trial Found

Does Equelle work for hot flashes?

This is not medical advice — it is general information based on what you searched for that may help.

General information based on published sources and the symptoms you searched for. This isn't medical or legal advice, a diagnosis or a treatment plan. Please consult a doctor about your own symptoms. If your symptoms are severe or sudden, seek urgent care.

Our verdict: Limited evidence — one genuinely positive, well-designed trial, not yet independently replicated.

Equelle's ingredient, S-equol, is one of the more scientifically interesting entries in the menopause supplement aisle, and the one real trial behind it is worth taking seriously — while still being honest about what "one trial" does and doesn't prove.

The biology behind it

About 20–30% of people (and a smaller share of non-Asian populations) have gut bacteria that convert daidzein, a compound in soy, into S-equol, which has estrogen-like activity. People who don't produce it naturally are called "equol non-producers." Equelle's premise is to supply S-equol directly, bypassing the need for that gut conversion — which is why the key trial specifically recruited women who don't make it naturally.

What the trial actually found

A multicenter, double-blind, placebo-controlled trial recruited 160 postmenopausal Japanese women who were confirmed equol non-producers and who experienced at least one hot flush per day. They took either 10 mg/day of natural S-equol or a placebo for 12 weeks. Results:

Hot flush frequency dropped 58.7% in the S-equol group versus 34.5% with placebo — a statistically significant difference (p=0.009)
Hot flush severity and neck or shoulder muscle stiffness also decreased significantly more than placebo
No serious adverse effects were reported

The researchers themselves describe this as "the first trial" to show this effect, which is an important detail: a real, well-designed, statistically significant result, but a first result, not a settled one.

Why we're grading this Limited, not higher

Our evidence grades reflect the overall weight of evidence a treatment has built up, not just whether one trial succeeded. This is a single trial, in one population (postmenopausal Japanese women), with a 12-week follow-up. Good trial design (randomized, double-blind, placebo-controlled) is a real strength, but it hasn't yet been confirmed by independent replication in other populations, including the non-Asian equol non-producers who make up much of this product's target market in the US.

That's a meaningfully better starting point than several other supplements on our does it work? directory — this isn't a "not supported" verdict — but it's not yet the kind of broadly replicated, guideline-reviewed evidence base that earns a Moderate or Strong grade.

What to consider

A genuinely positive single trial exists for this specific ingredient and dose (10mg/day S-equol)
Not yet independently replicated across broader populations
If you want options with a larger, independently reviewed evidence base for hot flashes specifically, see our does it work? evidence checker or non-hormonal prescription options

Am I likely an "equol non-producer," and does that change how relevant this specific trial's population is to me?
Would it make sense to try this for a defined trial period and track results against a guideline-recommended option?

Where are you right now?

Still tracking

Not sure if your symptoms fit? Start tracking your daily patterns.

Log and spot your patterns with the symptom checklist →

Ready to talk to a doctor

Have an upcoming appointment? Bring structured questions and your history.

Prepare your 10-minute doctor appointment questions →

Already on treatment

Evaluating your response or wondering what to adjust next?

Explore evidence-graded treatment and lifestyle options →

Questions people ask

Does Equelle actually reduce hot flashes?

The one real placebo-controlled trial of its active ingredient, S-equol, is genuinely positive: 160 postmenopausal women who don't naturally produce S-equol from soy took either 10mg/day of S-equol or a placebo for 12 weeks. The S-equol group had significantly fewer hot flashes (-58.7% vs. -34.5% reduction, a statistically significant difference, p=0.009) and less severity, with no serious side effects. That's a real result, not a marketing exaggeration.

Why is this graded Limited if the trial was positive?

Because it's one trial, in one specific population (postmenopausal Japanese women who don't produce S-equol naturally), over 12 weeks. A positive result in a well-designed single trial is a genuinely good sign, but our grading reflects the overall weight of evidence, including independent replication across different populations — which this specific ingredient hasn't yet accumulated the way guideline-recommended treatments have. We'd grade this higher if the result were confirmed by further independent trials.